Prevalence and Molecular Characterization of Carbapenemase Producing P. aeruginosa from Clinical Isolates in Tertiary Care Hospital
Paper Details
Prevalence and Molecular Characterization of Carbapenemase Producing P. aeruginosa from Clinical Isolates in Tertiary Care Hospital
Abstract
Carbapenemases are β-lactamases with hydrolytic capacities and can hydrolyze penicillin, monobactams, carbapenems, and cephalosporins. Bacteria producing these β-lactamases renders many β-lactams ineffective and thus may cause serious infections. This study was designed to investigate the prevalence and molecular characterization of Carbapenemase producing Pseudomonas aeruginosa from clinical isolates in tertiary hospital to identify its prevalence. This study was conducted at the department of Microbiology, Microbiology Research Laboratory of Quaid-i-Azam University. Antibiotic susceptibility testing and phenotypic screening for MBLs were performed on 150 P. aeruginosa isolates which were collected from department of Microbiology Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad Pakistan. MICs were determined and Carbapenemase genes were sought by PCR. The resistant rate to imipenem was 34.6 %. The resistance rates of P. aeruginosa to levofloxacin, ciprofloxacin, tobramycin, Ceftazidime, Meropenam, Aztreonam, Amikacin, cefaperazone/sulbactam and piperacillin/tazobactam were 43.3%, 40.1%, 40.1%, 34.6%, 34.6%, 26.6%, 25.3%, 20.1% and 15.3% respectively. Piperacillin+tazobactum (15.3%) were observed to be the most effective. The point prevalence of Multi-Drug-Resistant (MDR) P. aeruginosa showed 56%, The MIC of 35 isolates showed no zone of inhibition under the potential range of E-test strips and thus have MIC > 32 µg/ml showing the high level of resistance to imipenem. Modified Hodge Test (MHT) was used for screening of Carbapenemase which showed 71% (n=37 out of 52) and for Metallo-beta-lactamase (MBL) screening with EDTA it showed 100% positive. PCR was used for the confirmation of 52 positive samples which indicated that 23 (44%) of the isolates were positive for (IMP) gene. A total of 11 isolates (21%) were positive for (VIM) resistant gene while 7 isolates were identified positive for IMP and VIM genes showing a high prevalence of MDR strains.
Ali Z. 2015. “Multi-Drug Resistant Pseudomonas Aeruginosa: A threat of nosocomial infections in tertiary care hospitals.” Journal of Pakistan Medical Association 65(12).
Ameen N. 2015. “Imipenem Resistant Pseudomonas aeruginosa: The fall of the final quarterback.” Pakistan journal of medical sciences.” 31(3), 561-570. http://dx.doi.org/10.12669/pjms.313.7372.
Amudhan MS. 2012. “blaIMP and blaVIM mediated carbapenem resistance in Pseudomonas and Acinetobacter species in India.” The Journal of Infection in Developing Countries 6(11), 757-762.
Bashir D. 2011. “Detection of metallo-beta-lactamase (MBL) producing Pseudomonas aeruginosa at a tertiary care hospital in Kashmir.” African Journal of Microbiology Research 5(2), 164-172.
Chen WP, Kuo T. 1993. “A simple and rapid method for the preparation of gram-negative bacterial genomic DNA.” Nucleic acids research 21(9), 2260.
Doosti M. 2013. “Identification and characterization of metallo-β-lactamases producing Pseudomonas aeruginosa clinical isolates in University Hospital from Zanjan Province, Iran.” Iranian biomedical journal 17(3), 129.
Engel J, Balachandran P. 2009. “Role of Pseudomonas aeruginosa type III effectors in disease.” Current opinion in microbiology 12(1), 61-66.
Gill MM. 2011. “Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa.” J Coll Physicians Surg Pak 21(9), 531-534.
Hirsch EB, Tam VH. 2010. “Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes.”
Jácome PRLDA. 2012. “Phenotypic and molecular characterization of antimicrobial resistance and virulence factors in Pseudomonas aeruginosa clinical isolates from Recife, State of Pernambuco, Brazil.” Revista da Sociedade Brasileira de Medicina Tropical 45(6), 707-712.
Khan F. 2014. “Prevalence and susceptibility pattern of multi drug resistant clinical isolates of Pseudomonas aeruginosa in Karachi.” Pakistan journal of medical sciences 30(5), 951.
Khan JA IZ, Rahman SU, Farzana K, Khan A. Report. 2008. ” prevalence and resistance pattern of Pseudomonas aeruginosa against various antibiotics. .” Pak J Pharm Sci.
Kohlenberg A. 2010. “Outbreak of carbapenem-resistant Pseudomonas aeruginosa infection in a surgical intensive care unit.” Journal of Hospital Infection 74(4), 350-357.
Lee K. 2001. “Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobactet species.” Clinical microbiology and infection 7(2), 88-91.
Mulcahy LR. 2014. “Pseudomonas aeruginosa biofilms in disease.” Microbial ecology 68(1), 1-12.
Naqvi ZA. 2005. “Multidrug resistant Pseudomonas aeruginosa: a nosocomial infection threat in burn patients.” Pakistan J Pharma 22(2), 9-15.
Ullah F. 2009. “Antimicrobial susceptibility and ESBL prevalence in Pseudomonas aeruginosa isolated from burn patients in the North West of Pakistan.” Burns 35(7), 1020-1025.
Vahdani M. 2012. “Phenotypic screening of extended-spectrum ß-lactamase and metallo-ß-lactamase in multidrug-resistant Pseudomonas aeruginosa from infected burns.” Annals of burns and fire disasters 25(2), 78. http://dx.doi.org/10.5897/AJMR2013.6194.
Wayne P. 2006. Clinical and Laboratory Standarts Institute: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow Aerobically, Approved Standart M7-A7, CLSI, USA.
Yang M. 2011. “Pseudomonas aeruginosa bacteremia in children over ten consecutive years: analysis of clinical characteristics, risk factors of multi-drug resistance and clinical outcomes.” Journal of Korean medical science 26(5), 612-618.
Syeda Farishta, Tanveer Ahmad, Asif Jamal, Amir Ali Shah, 2020. Prevalence and Molecular Characterization of Carbapenemase Producing P. aeruginosa from Clinical Isolates in Tertiary Care Hospital. Int. J. Biosci., 16(2), 302-311.
Copyright © 2020 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.